Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 1/2022

01-01-2022 | Venous Thrombosis | Stroke (DL Tirschwell, Section Editor)

Updates in Cerebral Venous Thrombosis

Authors: Arshia Alimohammadi, Diana J. Kim, Thalia S. Field

Published in: Current Cardiology Reports | Issue 1/2022

Login to get access

Abstract

Purpose of Review

Cerebral venous thrombosis (CVT) is a rare cause of stroke that most commonly affects younger women. Here, we review new literature relevant to the management and prognosis of individuals with CVT and ongoing areas of uncertainty.

Recent Findings

Direct-acting oral anticoagulants (DOACs) are being increasingly integrated into routine care but are not yet recommended by guidelines. Recent randomized clinical trials and available case series offer reassuring safety data. Routine use of endovascular therapy is not associated with improved outcomes. The relationship between recanalization and prognosis is uncertain.

Summary

The evidence base for management of CVT continues to improve. Ongoing areas of uncertainty include duration of therapy and whether certain subgroups of patients may benefit from neurointervention or personalized approaches to antithrombotic strategy. The state of knowledge will continue to benefit from large collaborative international efforts, and integration of patient partnerships to identify research priorities.
Literature
1.
Bousser M-G, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol. 2007;6:162–70.PubMed
2.
Shatzel JJ, O’Donnell M, Olson SR, Kearney MR, Daughety MM, Hum J, et al. Venous thrombosis in unusual sites: a practical review for the hematologist. Eur J Haematol. 2019;102:53–62.PubMed
3.
Canhão P, Ferro JM, Lindgren AG, Bousser M-G, Stam J, Barinagarrementeria F, et al. Causes and predictors of death in cerebral venous thrombosis. Stroke. 2005;36:1720–5.PubMed
4.
Coutinho JM, Ferro JM, Canhão P, Barinagarrementeria F, Cantú C, Bousser M-G, et al. Cerebral venous and sinus thrombosis in women. Stroke. 2009;40:2356–61.PubMed
5.
Koopman K, Uyttenboogaart M, Vroomen PC, van der Meer J, De Keyser J, Luijckx G-J. Long-term sequelae after cerebral venous thrombosis in functionally independent patients. J Stroke Cerebrovasc Dis. 2009;18:198–202.PubMed
6.
Hiltunen S, Putaala J, Haapaniemi E, Tatlisumak T. Long-term outcome after cerebral venous thrombosis: analysis of functional and vocational outcome, residual symptoms, and adverse events in 161 patients. J Neurol. 2016;263:477–84.PubMed
7.
Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:1158–92.PubMed
8.
Ferro JM, Bousser M-G, Canhão P, Coutinho JM, Crassard I, Dentali F, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. Eur J Neurol. 2017;24:1203–13.PubMed
9.
• Ulivi L, Squitieri M, Cohen H, Cowley P, Werring DJ. Cerebral venous thrombosis: a practical guide. Pract Neurol. 2020;20:356–67. Comprehensive review focused on current standards for clinical management.
10.
Durmuș B, Yperzeele L, Zuurbier SM. Cerebral venous thrombosis in women of childbearing age: diagnosis, treatment, and prophylaxis during a future pregnancy. Ther Adv Neurol Disord. 2020;13:1756286420945169.PubMedPubMedCentral
11.
de Sousa DA. Cerebral venous thrombosis: what’s new? Hamostaseologie. 2021;41:025–30.
12.
Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38:S495–501.PubMed
13.
Coutinho JM, Zuurbier SM, Aramideh M, Stam J. The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke. 2012;43:3375–7.PubMed
14.
Devasagayam S, Wyatt B, Leyden J, Kleinig T. Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study. Stroke. 2016;47:2180–2.PubMed
15.
Kristoffersen ES, Harper CE, Vetvik KG, Zarnovicky S, Hansen JM, Faiz KW. Incidence and mortality of cerebral venous thrombosis in a Norwegian population. Stroke. 2020;51:3023–9.PubMed
16.
Ruuskanen JO, Kytö V, Posti JP, Rautava P, Sipilä JOT. Cerebral venous thrombosis: Finnish nationwide trends. Stroke. 2021;52:335–8.PubMed
17.
• Otite FO, Patel S, Sharma R, Khandwala P, Desai D, Latorre JG, et al. Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States. Neurology. 2020;95:e2200–13. Describes US trends in increasing incidence of CVT by sex and race-ethnicity.
18.
•• Ken-Dror G, Cotlarciuc I, Martinelli I, Grandone E, Hiltunen S, Lindgren E, et al. Genome-wide association study identifies first locus associated with susceptibility to cerebral venous thrombosis. Ann Neurol. 2021. https://​doi.​org/​10.​1002/​ana.​26205. GWAS study in individuals with CVT.
19.
White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107:I4-8.
20.
Swartz RH, Cayley ML, Foley N, Ladhani NNN, Leffert L, Bushnell C, et al. The incidence of pregnancy-related stroke: a systematic review and meta-analysis. Int J Stroke. 2017;12:687–97.PubMed
21.
Silvis SM, Middeldorp S, Zuurbier SM, Cannegieter SC, Coutinho JM. Risk factors for cerebral venous thrombosis. Semin Thromb Hemost. 2016;42:622–31.PubMed
22.
Zuurbier SM, Arnold M, Middeldorp S, Broeg-Morvay A, Silvis SM, Heldner MR, et al. Risk of cerebral venous thrombosis in obese women. JAMA Neurol. 2016;73:579–84.PubMed
23.
• Green M, Styles T, Russell T, Sada C, Jallow E, Stewart J, et al. Non-genetic and genetic risk factors for adult cerebral venous thrombosis. Thromb Res. 2018;169:15–22. Comprehensive meta-analysis of case-control studies examining risk factors for CVT.
24.
• Baldini T, Asioli GM, Romoli M, Carvalho Dias M, Schulte EC, Hauer L, et al. Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus-2 infection: a systematic review and meta-analysis. Eur J Neurol. 2021. https://​doi.​org/​10.​1111/​ene.​14727. Most current meta-analysis examining CVT in SARS-CoV-2 infection.
25.
26.
Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine. 2020;29:100639.
27.
28.
Krzywicka K, Heldner MR, Sánchez van Kammen M, van Haaps T, Hiltunen S, Silvis SM, et al. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency. Eur J Neurol. 2021. https://​doi.​org/​10.​1111/​ene.​15029.
29.
30.
31.
Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384:2124–30.PubMed
32.
Makris M, Pavord S, Lester W, Scully M, Hunt B. Vaccine-induced immune thrombocytopenia and thrombosis (VITT). Res Pract Thromb Haemost. 2021;5:e12529.
33.
34.
Warkentin TE, Greinacher A. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia. Thromb Res. 2021;204:40–51.PubMed
35.
Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384:2202–11.PubMed
36.
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384:2092–101.PubMed
37.
Sánchez van Kammen M, Heldner MR, Brodard J, Scutelnic A, Silvis S, Schroeder V, et al. Frequency of thrombocytopenia and platelet factor 4/heparin antibodies in patients with cerebral venous sinus thrombosis prior to the COVID-19 pandemic. JAMA. 2021;326:332–338.
38.
•• Huynh A, Kelton JG, Arnold DM, Daka M, Nazy I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature. 2021;596:565–9. Discusses the difference in antibody targets for vaccine-induced thrombotic thrombocytopenia versus heparin-induced thrombocytopenia.
39.
Bikdeli B, Chatterjee S, Arora S, Monreal M, Jimenez D, Krumholz HM, et al. Cerebral venous sinus thrombosis in the U.S. population, after adenovirus-based SARS-CoV-2 vaccination, and after COVID-19. J Am Coll Cardiol. 2021;78:408–11.PubMedPubMedCentral
40.
Patriquin CJ, Laroche V, Selby R, Pendergrast J, Barth D, Côté B, et al. Therapeutic plasma exchange in vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med. 2021;385:857–9.PubMed
41.
•• Rizk JG, Gupta A, Sardar P, Henry BM, Lewin JC, Lippi G, et al. Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: a review. JAMA Cardiol. 2021. https://​doi.​org/​10.​1001/​jamacardio.​2021.​3444. Overview of treatment of CVT associated with vaccine-induced thrombotic thrombocytopenia.
42.
Idiculla PS, Gurala D, Palanisamy M, Vijayakumar R, Dhandapani S, Nagarajan E. Cerebral venous thrombosis: a comprehensive review. Eur Neurol. 2020;83:369–79.PubMed
43.
Ferro JM, Canhão P, Stam J, Bousser M-G, Barinagarrementeria F, ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664–70.PubMed
44.
Duman T, Uluduz D, Midi I, Bektas H, Kablan Y, Goksel BK, et al. A multicenter study of 1144 patients with cerebral venous thrombosis: the VENOST Study. J Stroke Cerebrovasc Dis. 2017;26:1848–57.PubMed
45.
Ferro JM, Canhão P, Bousser M-G, Stam J, Barinagarrementeria F, ISCVT Investigators. Cerebral vein and dural sinus thrombosis in elderly patients. Stroke. 2005;36:1927–32.PubMed
46.
Lindgren E, Silvis SM, Hiltunen S, Heldner MR, Serrano F, de Scisco M, et al. Acute symptomatic seizures in cerebral venous thrombosis. Neurology. 2020;95:e1706–15.PubMed
47.
Girot M, Ferro JM, Canhão P, Stam J, Bousser M-G, Barinagarrementeria F, et al. Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage. Stroke. 2007;38:337–42.PubMed
48.
Ortega-Gutierrez S, Holcombe A, Aksan N, Dai B, Shaban A, Lazarre L, et al. Association of admission clinical predictors and functional outcome in patients with cerebral venous and dural sinus thrombosis. Clin Neurol Neurosurg. 2020;188:105563.
49.
Busch MA, Hoffmann O, Einhäupl KM, Masuhr F. Outcome of heparin-treated patients with acute cerebral venous sinus thrombosis: influence of the temporal pattern of intracerebral haemorrhage. Eur J Neurol. 2016;23:1387–92.PubMed
50.
von Kummer R, Broderick JP, Campbell BCV, Demchuk A, Goyal M, Hill MD, et al. The Heidelberg Bleeding Classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke. 2015;46:2981–6.
51.
Qureshi A, Perera A. Low molecular weight heparin versus unfractionated heparin in the management of cerebral venous thrombosis: a systematic review and meta-analysis. Ann Med Surg (Lond). 2017;17:22–6.
52.
•• Coutinho JM, Zuurbier SM, Bousser M-G, Ji X, Canhão P, Roos YB, et al. Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis: the TO-ACT Randomized Clinical Trial. JAMA Neurol. 2020;77:966–73. Randomized clinical trial of endovascular therapy versus standard care in CVT.
53.
Ferro JM, Crassard I, Coutinho JM, Canhão P, Barinagarrementeria F, Cucchiara B, et al. Decompressive surgery in cerebrovenous thrombosis. Stroke. 2011;42:2825–31.
54.
Abstracts M. European Stroke Journal SAGE Publications. 2021;6:3–513.
55.
Salottolo K, Bartt R, Frei DF, Bellon RJ, Atchie B, McCarthy K, et al. Timing of anticoagulation in patients with cerebral venous thrombosis requiring decompressive surgery: systematic review of the literature and case series. World Neurosurg. 2020;137:408–14.PubMed
56.
Field TS, Camden M-C, Al-Shimemeri S, Lui G, Lee AY. Off-label use of novel anticoagulants for treatment of cerebral venous thrombosis: a Canadian survey. Int J Stroke. 2017;12:NP16–8.
57.
• Bose G, Graveline J, Yogendrakumar V, Shorr R, Fergusson DA, Le Gal G, et al. Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review. BMJ Open. 2021;11:e040212. Systematic review examining use of DOACs in CVT.
58.
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. Massachusetts Medical Society; 2012;366:1287–1297.
59.
Prins MH, Lensing AWA, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1:e37-46.PubMed
60.
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708.PubMed
61.
Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52.PubMed
62.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.PubMed
63.
•• Ferro JM, Coutinho JM, Dentali F, Kobayashi A, Alasheev A, Canhão P, et al. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol. 2019. https://​doi.​org/​10.​1001/​jamaneurol.​2019.​2764. Randomized clinical trial of dabigatran versus standard care in CVT.
64.
•• Connor P, Sánchez van Kammen M, Lensing AWA, Chalmers E, Kállay K, Hege K, et al. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv. 2020;4:6250–8. Substudy examining CVT cases in randomized clinical trial of rivaroxaban versus standard care in pediatric VTE.
65.
66.
• Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132:1365–71. Randomized clinical trial of rivaroxaban versus warfarin in high-risk APLAS.
67.
Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78:1296–304.PubMed
68.
Woller SC, Stevens SM, Kaplan DA, Rondina MT. Protocol modification of apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome study. Clin Appl Thromb Hemost. 2018;24:192.PubMed
69.
Lancet T. Raising awareness of antiphospholipid antibody syndrome. Lancet. 2010;375:778.
70.
Coutinho JM, Seelig R, Bousser M-G, Canhão P, Ferro JM, Stam J. Treatment variations in cerebral venous thrombosis: an international survey. Cerebrovasc Dis. 2011;32:298–300.PubMed
71.
Field TS, Camden M-C, Al-Shimemeri S, Lui G, Lee AYY. Antithrombotic strategy in cerebral venous thrombosis: differences between neurologist and hematologist respondents in a Canadian survey. Can J Neurol Sci. 2017;44:116–9.PubMed
72.
Miranda B, Aaron S, Arauz A, Barinagarrementeria F, Borhani-Haghighi A, Carvalho M, et al. The benefit of EXtending oral antiCOAgulation treatment (EXCOA) after acute cerebral vein thrombosis (CVT): EXCOA-CVT cluster randomized trial protocol. Int J Stroke. 2018;13:771–4.PubMed
73.
•• Aguiar de Sousa D, Lucas Neto L, Arauz A, Sousa AL, Gabriel D, Correia M, et al. Early recanalization in patients with cerebral venous thrombosis treated with anticoagulation. Stroke. 2020;51:1174–81. Prospective neuroimaging study examining early recanalization in CVT.
74.
75.
de Sousa DA, Lucas Neto L, Canhão P, Ferro JM. Recanalization in cerebral venous thrombosis. Stroke. 2018;49:1828–35.
76.
Ji K, Zhou C, Wu L, Li W, Jia M, Chu M, et al. Risk factors for severe residual headache in cerebral venous thrombosis. Stroke. 2021;52:531–6.PubMed
77.
• Palazzo Paola, Agius Pierre, Ingrand Pierre, Ciron Jonathan, Lamy Matthias, Berthomet Aline, et al. Venous thrombotic recurrence after cerebral venous thrombosis. Stroke. Am Heart Assoc. 2017;48:321–6. Systematic review and prospective study examining recurrence rates for CVT and risk factors.
78.
• Pires GS, Ribeiro DD, Oliveira JAQ, Freitas LC, Vaez R, Annichino-Bizzacchi JM, et al. Risk factors associated with recurrent venous thromboembolism after a first cerebral venous thrombosis event: a cohort study. Thromb Res. 2019;178:85–90. Prospective study examining recurrence rates in lower-risk individuals with CVT.
79.
•• Sánchez van Kammen M, Lindgren E, Silvis SM, Hiltunen S, Heldner MR, Serrano F, et al. Late seizures in cerebral venous thrombosis. Neurology. 2020;95:e1716–23. Prospective study describing the natural history of seizures after CVT.
80.
Ferro JM, Coutinho JM, Jansen O, Bendszus M, Dentali F, Kobayashi A, et al. Dural arteriovenous fistulae after cerebral venous thrombosis. Stroke. 2020;51:3344–7.PubMed
81.
Eypasch E, Lefering R, Kum CK, Troidl H. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ. 1995;311:619–20.PubMedPubMedCentral
82.
Preter M, Tzourio C, Ameri A, Bousser MG. Long-term prognosis in cerebral venous thrombosis. Follow-up of 77 patients. Stroke. 1996;27:243–6.PubMed
83.
Metadata
Title
Updates in Cerebral Venous Thrombosis
Authors
Arshia Alimohammadi
Diana J. Kim
Thalia S. Field
Publication date
01-01-2022
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 1/2022
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-021-01622-z

Other articles of this Issue 1/2022

Current Cardiology Reports 1/2022 Go to the issue

Correction

Correction to: Stroke Prevention in Cervical Artery Dissection

New Therapies for Cardiovascular Disease (AA Bavry and MR Massoomi, Section Editors)

Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis

Congenital Heart Disease (RA Krasuski and G Fleming, Section Editors)

Covered Stents in the Management of Aortic Coarctation and Right Ventricular Outflow Tract Obstruction

Correction

Correction to: Rilonacept (Interleukin‑1 Inhibition) for the Treatment of Pericarditis

Ischemic Heart Disease (D Mukherjee, Section Editor)

Contemporary Review of Risk Scores in Prediction of Coronary and Cardiovascular Deaths

Ischemic Heart Disease (D Mukherjee, Section Editor)

The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits